Semaglutide kidney trial maps how Ozempic-class drugs may slow diabetic kidney damage

A 52-week randomized trial published Oct. 1 in Nature Medicine offers the clearest human-tissue look yet at how the GLP-1 receptor agonist semaglutide may protect kidneys in people with type 2 diabetes and chronic kidney disease — even as its main MRI endpoints missed statistical significance. In the REMODEL trial (NCT04865770), 106 participants were randomized 2:1 to subcutaneous semaglutide 1 mg once weekly or placebo. Coprimary multiparametric MRI outcomes — kidney oxygenation (R2*), global perfusion and T1 inflammation mapping — were not significantly different between groups after a year. Secondary imaging, however, showed a lower renal artery resistive index and higher cortical apparent diffusion coefficient with semaglutide, findings the authors interpret as reduced vascular resistance and prevention of fibrosis progression. Exploratory clinical signals included a roughly 40% drop in urinary albumin-to-creatinine ratio versus placebo and higher 24-hour creatinine clearance; body weight and HbA1c also fell more with the drug, as expected. Paired kidney biopsies with single-nucleus RNA sequencing and spatial transcriptomics pointed to glomerular endothelial cells as the most treatment-responsive populations, with reduced nearby immune cells after semaglutide and gene-expression shifts tied to metabolic stress, inflammation and fibrosis pathways. Histology suggested a smaller fractional intimal area in the most diseased arterioles. The trial was funded by Novo Nordisk, maker of semaglutide products, and several authors are company employees or consultants; results should be read alongside the larger FLOW outcomes trial rather than as a new prescribing mandate. For Canadian clinicians already pairing GLP-1 drugs with SGLT2 inhibitors, REMODEL’s mechanistic map — lower kidney fat, improved microvascular signals, endothelial transcript changes — helps explain outcome benefits beyond weight loss, while underscoring that MRI coprimaries were negative and the biopsy subgroup was small. This article summarizes peer-reviewed research for general information only. It is not a substitute for professional medical advice, diagnosis or treatment. Consult a qualified clinician before changing any medication or care plan. Sources: Nature Medicine Effects of semaglutide on kidney disease in type 2 diabetes; ClinicalTrials.gov NCT04865770.